Cambridge Cognition Share Discussion Threads

[woodcutter] 21/11/2015 10:33

watching with interest but not yet invested. I like the ideas behind the business product but looks very much like there'll be a cash call to me. now on my tier 1 watch list.

Hopefully i can get invested before i become a client ;-)

woody

[phowdo] 20/11/2015 07:53

I think you would have to compare to the interims where they were showing a loss of 280k - so flat in the 2nd half despite increased investment in commercial?
The new contracts are encouraging.

[imranawan] 20/11/2015 07:47

Thats what I thought as well WJCCGHCC. Also the $4.5m worth of contracts will be recognised in the current yer through to 2017. It doesn't provide a split.

[battlebus2] 20/11/2015 07:44

Depends how you read the situation with clearly increased investment in 2015 but material growth for 2016.

M/Cap only 14 million looks cheap to me after this mornings news.

[wjccghcc] 20/11/2015 07:38

Isn't it a warning? Forecasts were for a PBT of 300k but they say the outturn is similar to 2014 i.e. a loss of 290k?

[janeann] 20/11/2015 07:14

Very positive update;

Cambridge Cognition Holdings plc, (AIM: COG), a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m including upfront payments and revenues to be recognized in the current year and through to 2017.

The potential for these contracts was highlighted in the interim results and they ensure that, despite increasing investment in both healthcare technology development and commercial infrastructure in the USA, the outturn for this year should be similar to 2014 and provide a strong contracted revenue base for the next fiscal year. Accordingly 2016 is expected to be a year of material growth as the Company continues to make significant commercial and technological advances.

Commenting on the results Steven Powell, Chief Operating Officer, said:

"We are pleased to have made significant progress in our pharmaceutical clinical trials business and these contracts provide a strong foundation for continued growth in 2016."

[playful] 06/10/2015 14:13

I forgot I had them...

[phowdo] 02/10/2015 12:30

I think it is probably one buyer pushing the price combined with a dearth of sellers supplying stock. Theres been 5k,10k sized buys ever since the results.

I bought some (not as many as I had before) back after that corporate health RNS as I think that has great potential if they get it right. Look at how much corporations spend on Myers Briggs type personality tests, drug tests and physical health tests for their employees.
However their cash position is a bit low so it wouldn't surprise me if the brokers are on the phone to the CEO itching to earn fees for a placing. For that reason Im not adding any more. Someone is happy to though...

[battlebus2] 01/10/2015 21:52

Anyone know of the reasoning behind the new highs, last couple of days have seen a sharp mark up....

[phowdo] 10/9/2015 14:02

Disappointing that they haven't reached breakeven yet.
Alas, it now raises the question as to whether they may need to raise more money in the near future.
I dont think I'll be buying back in just yet.

Edit:
The corporate health initiative could be a very nice business.
Since results someone is buying up any loose stock and its actually hard to buy in size now.

[battlebus2] 09/9/2015 08:41

New patent application

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces that a second patent application has been filed in the field of systems and methods for assessing cognitive function describing ways of using wearable technology, smartphones and other consumer electronics to measure cognitive function in peoples' own homes.

By mapping data from proprietary cognitive assessments to usage and behavioural trends of new devices and popular games the invention will monitor cognitive health and detect impairments such as ADHD, depression and dementia before noticeable symptoms develop. This would have application for both consumer-led mental health management and in improving pharmaceutical drug development through long-term monitoring of cognitive function.

This patent will extend the Company's IP asset estate adding to the technology value of the Company. The method of using new consumer technologies to monitor brain function and provide an early indication of impairment is highly innovative and is an area of significant growth potential for future products and commercial partnerships.

Using novel devices to monitor cognitive function and identify early deterioration is in line with the Company'sstrategic vision to become a leader in cognitive assessment technology in global healthcare markets. This follows another of the Company's recently filed patents surrounding the use of wearable technology for assessing cognitive function and symptoms of neurological and neuropsychiatric conditions, announced on May 6 2015.

Cambridge Cognition has a proven record of innovation, having recently introduced the first clinically approved touchscreen assessment for Alzheimer's disease into the NHS, which has now been used to test over 20,000 patients and developed a portfolio of cloud-based cognitive assessment products to enhance safe and effective pharmaceutical development. The global wearable healthcare market is expected to expand to $41 billion by 2020, from $2 billion in 2014 (Soreon Research, 2014) corroborating the Company's recent investment in IP assets and strategic development programmes.

Steven Powell, Chief Operating Officer of Cambridge Cognition, said: "The unique technology around this patent allows the detection of cognitive impairments to be performed on a continuous basis, without time, expense or inconvenience for the subject or healthcare provider. Ubiquitous monitoring of big data using our cloud technology can enable interventions to be immediate and will have a significant positive impact on patient care, empowering more effective management of mental health and wellbeing."

[battlebus2] 20/8/2015 07:43

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will be reporting its interim results for the six months ended 30 June 2015 on Thursday 10 September 2015.

[kiwimonk] 16/7/2015 18:13

The Best Question to ask someone to determine whether they have Dementia is

"Can you say your name"

If they say their proper Name, they're A-OK

If they say "Your Name" They're A-OK

See? it's all a load of BS

NHS Young Doctors are mentally ill equipped to diagnose anything other than a broken Bone

[kiwimonk] 16/7/2015 18:06

what's this gangs computer program?

"can you input your password?"

"Incorrect Password, you have Dementia"

[kiwimonk] 16/7/2015 18:05

dementia = natural cell death = old age

[minkob] 16/7/2015 17:22

Looks like another Ultrasis to me

[2breakout] 08/6/2015 10:37

so they have a teach in to see if they can get a few punters to buy here, then the director sells 150,000!

[mammyoko] 04/6/2015 09:12

Looks like their Chief Brains is off to pastures new from yesterday's RNS

[phowdo] 03/6/2015 11:05

Nice little write-up of the teach-in by Paul Scott.

[phowdo] 27/5/2015 11:09

Thanks battlebus,

From the newswires, it seems FinnCap have a target of 300k which is corresponds to your 1.7p eps.

[battlebus2] 27/5/2015 08:02

I have noted revenues of 7.2 with an EPS of 1.7p but haven't seen any recent notes..

[phowdo] 27/5/2015 07:48

Anyone know the actual "market expectations" figures?

[battlebus2] 27/5/2015 07:08

AGM statement.

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

As I outlined in our Preliminary Results statement our financial performance remains in line with market expectations.

The contribution from our clinical trials and academic businesses continued to grow in the first quarter. In particular the enlarged US sales team offers an opportunity to enhance both clinical and academic sales in North America and we already have a healthy pipeline of contracts in the safety and tolerability trial space that we expect to convert over the remainder of the year.

The return to profitability in our clinical trials and academic businesses enables us to increase investment in our early stage healthcare technology business which bodes well for the future prospects of the Company.

[janeann] 20/5/2015 07:37

Very positive - this area of the companys activity is what prompted me to invest in the first place so good to see real progress here

[battlebus2] 20/5/2015 07:23

Development of Alzheimer's treatments to be accelerated with new Cambridge Cognition product

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the launch of a new cloud based cognitive assessment product to accelerate development of Alzheimer's disease treatments, Cantab Connect Alzheimer's.

The global market for Alzheimer's disease treatment is expected to more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023, making the race to develop disease-modifying therapies big business for the pharmaceutical industry. In order to achieve this, more sensitive analytical tools are required to identify drugs that can alter the course of the disease. The Cantab Connect Alzheimer's cognitive assessment product provides sensitive measures that are far more effective than traditional paper-based tests, enabling pharmaceutical companies to increase the chances of identifying new drugs that have positive effects on Alzheimer's patients and gaining subsequent regulatory and market approval.

The market size of cognitive assessments in Alzheimer's disease trials is estimated to be in excess of $17m. With over thirty Alzheimer's trials already completed using proprietary Cambridge Cognition products, the Company forecast this to be an increasing area of growth potential following the launch of Cantab Connect Alzheimer's.

Nick Kerton, Chief Executive Officer of Cambridge Cognition Holdings plc commented: "Cambridge Cognition has become synonymous with innovation in healthcare, research and development for Alzheimer's. Today we launch the first in a series of cognitive assessment software products to support effective development of new drugs across a range of disease areas. With the capabilities of our cloud technology combined with acutely sensitive measures of brain function, pharmaceutical companies can now conduct large, objective and reliable studies in clinical development to combat the disease quicker."